Hims & Hers faces profit crunch despite growth
The bear case argued for Hims & Hers: the company is losing more money on higher revenues, creating uncertainty as it seeks a new growth engine beyond compounded GLP-1 drugs.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.